Explore 3 Stock Ideas & Industry Insights Download Free Report

Announcements

Director John Frederick Gets 25,000 Stock Options at $0.74

A Form 4 filed on November 2, 2026, discloses that John W. Frederick, a director of Tempest Therapeutics, Inc. (NASDAQ:TPST), was granted a stock option to purchase 25,000 shares of common stock on October 13, 2026, at an exercise price of $0.74 per share.

Shwetambri Chauhan | 02 November 2026

John Frederick Joins Tempest Therapeutics Board, Holds 8,000 Shares

Director John W. Frederick filed an initial statement of beneficial ownership with the SEC on November 2, 2026, reporting his holdings in Tempest Therapeutics, Inc. as of the event date of October 13, 2026.

Anjali Anand | 02 November 2026

Micheal G. Dunn Files Initial Ownership Statement for MPLX LP

Micheal G. Dunn, a newly appointed director of MPLX GP LLC, filed a Form 3 initial statement of beneficial ownership with the SEC on November 2, 2026, reporting zero directly held Common Units of MPLX LP as of the triggering event date of November …

Anjali Anand | 02 November 2026

Bruce L. Niemeyer Files Form 3 as MPLX LP Director

Bruce L. Niemeyer filed an Initial Statement of Beneficial Ownership with the SEC on November 2, 2026, disclosing his status as a newly reporting director of MPLX LP, effective November 1, 2026.

Aakashdeep | 02 November 2026

Charles Silberstein Files Form 3 as CFO of NovaBridge Biosciences

Charles Silberstein, Chief Financial Officer of NovaBridge Biosciences, filed an initial statement of beneficial ownership on November 2, 2026, reporting no securities beneficially owned.

Vinay Lochav | 02 November 2026

Horich Receives 100,000 RSUs Tied to Supernus Merger Closing

William Todd Horich, SVP of Commercial Operations at Supernus Pharmaceuticals, Inc., filed a Form 4 on November 2, 2026, disclosing the acquisition of 100,000 restricted stock units on October 30, 2026.

Nitish Kishor | 02 November 2026

Frank Mottola Receives 100,000 RSUs Tied to Supernus Merger

Frank Mottola, SVP and Chief Technology Operations Officer of Supernus Pharmaceuticals, Inc., filed a Form 4 on November 2, 2026, disclosing the acquisition of 100,000 restricted stock units on October 30, 2026.

Shwetambri Chauhan | 02 November 2026

Supernus CFO Timothy Dec Receives 70,000 RSUs Tied to Merger

Supernus Pharmaceuticals, Inc. Senior Vice-President and CFO Timothy C. Dec filed a Form 4 on November 2, 2026, disclosing the acquisition of 70,000 restricted stock units on October 30, 2026.

Manish Choudhary | 02 November 2026

Jack Khattar Gets 400,000 RSUs Tied to Supernus-Indivior Merger

Supernus Pharmaceuticals President and CEO Jack A. Khattar filed a Form 4 on November 2, 2026, disclosing the acquisition of 400,000 restricted stock units on October 30, 2026, with vesting tied to the closing of a planned merger with Indivior Pharmaceuticals, Inc.

Anjali Anand | 02 November 2026

Jonathan Rubin Gets 70,000 RSUs Tied to Supernus Merger Close

Jonathan Rubin, SVP and Chief Medical Officer of Supernus Pharmaceuticals, Inc., reported the acquisition of 70,000 restricted stock units on October 30, 2026, in a Form 4 filed with the SEC on November 2, 2026.

Manish Choudhary | 02 November 2026
Support

Hi! How can we help you today?

Loading…